QurAlis Corporation

About QurAlis Corporation

QurAlis is a company of 'neuro pioneers' dedicated to exploring human neurology to discover and develop precision medicines for neurodegenerative and neurological diseases like ALS and FTD. Their mission is driven by the belief that a cure or treatment should exist for every disease and every person, with a relentless pursuit of knowledge and optimism to alter disease trajectories.

Products & Services

QRL-101:A potentially best-in-class selective Kv7.2/7.3 ion channel opener for ALS patients, currently in Phase 1 clinical trials.

FlexASO(r) Platform:A proprietary anti-sense oligonucleotide splice modulator platform designed to tackle the spectrum of neurodegenerative and neurological diseases.

Pipeline Candidates:Therapeutic candidates targeting specific components of ALS pathology and defined ALS patient populations based on genetic mutations and clinical biomarkers.

Specialties

Neurodegenerative Diseases Neurological Diseases Precision Medicines for ALS and FTD Anti-Sense Oligonucleotide Technology TDP-43 Pathology Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 88000000 MR: - FA: $88 million FAN: 88000000	D: 2023-03-09 FD: 2023-03-09	14 investors

Series B Latest

2023-03-09

$88.0M

14 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kevin Eggan

Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical

B

Brown

R

Rosen

Y

Yamanaka

W

Woolf

W

Wainger

View 35 more team members with Pro

Unlock Full Team Directory

Recent News